Clinical Characteristics of Patients Requiring a Second Dose of Radioactive Iodine for the Treatment of Graves’ Disease | oneGRAVESvoice

welcome to oneGRAVESvoice

- a positively charged Graves' disease and thyroid eye disease community.
  • join today!
Abstracts & Posters

Clinical Characteristics of Patients Requiring a Second Dose of Radioactive Iodine for the Treatment of Graves’ Disease

key information

source: Thyroid

year: 2018

authors: O’Keeffe DT, Abdullah A, Bell M

summary/abstract:

Graves’ disease is an autoimmune condition affecting the thyroid gland and is a common cause of hyperthyroidism. The main treatment goals are the reduction in thyroid hormone overproduction either with antithyroid drugs (ATD), surgery or radioactive iodine (RAI) therapy.

The aim of RAI (I-131) therapy is to treat hyperthyroidism by destroying sufficient thyroid tissue to render the patient either euthyroid or hypothyroid. The objective of this work was to examine the outcomes of RAI treatment for Graves’ disease in a large patient cohort over a two year period in a West of Ireland tertiary referral academic medical centre.

In particular, we focused on the characteristics of those patients requiring a second RAI administration. Institutional Review Board approval was obtained for this study and thereafter the clinical records of all the patients who underwent RAI treatment were examined. The data demonstrated that 150 patients underwent RAI treatment from Jan 2014 to Dec 2015.

organization: University Hospital Galway, Ireland

DOI: 10.1089/thy.2018.29065.abstracts